EDGAR·FLOW

Sunshine Biopharma Inc. — Form S-1

Filed November 18, 2026 · analyzed by the Registration Agent
S-1 ▲ Likely positive significance 72/100
What the filing says
Sunshine Biopharma Inc. (market cap ~$7.1M) executed a 1-for-20 reverse stock split effective October 20, 2026, combining every 20 shares into 1 share with fractional shares rounded up. Concurrently, the company filed a Form S-1 registration statement to offer 31,087,198 shares of common stock to the public. The reverse split reduces share count and nominally raises per-share price to meet listing standards; the S-1 seeks capital via primary offering.
Why this rating

Reverse split + IPO is material for $7.1M company—restructuring and capital raise could transform trajectory. However, outcome depends on demand and dilution; execution risk is high.

Tradability signal
NO TRADE

No trade: price $0.03 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$0.03
+10 min · unknown
$0.03 ▲ 0.00%
+30 min · unknown
$0.03 ▲ 0.00%
+1 hr · unknown
$0.03 ▲ 0.00%
+4 hrs · unknown
$0.03 ▲ 0.00%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ SBFMW · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.